🔗 Share this article

Chancellor Rachel Reeves has stated she is planning "targeted measures to tackle cost of living challenges" in the upcoming financial statement.

Speaking to the BBC, she emphasized that curbing price rises is a shared duty of both the government and the central bank.

The UK's inflation rate is forecast to be the most elevated among the Group of Seven industrialized countries this calendar year and the following year.

Possible Utility Bill Measures

It is understood the administration could intervene to reduce energy bills, such as by cutting the present 5% rate of VAT applied on energy supplies.

An additional approach is to cut some of the policy costs currently added to household expenses.

Budgetary Limitations and Expert Predictions

The government will receive the latest report from the independent fiscal watchdog, the Office for Budget Responsibility, on the start of the week, which will show how much room there is for these measures.

The view from the majority of analysts is that Reeves will have to declare higher taxes or expenditure reductions in order to fulfill her self-imposed fiscal targets.

Previously on Thursday, analysis suggested there was a £22bn gap for the Treasury chief to fill, which is at the lower end of expectations.

"There's a joint task between the central bank and the administration to continue tackling some of the sources of inflation," the Chancellor informed reporters in Washington, at the yearly gatherings of the International Monetary Fund and World Bank.

Revenue Commitments and International Issues

While much of the attention has been on expected tax rises, the chancellor said the most recent figures from the OBR had not changed her pledge to manifesto promises not to increase rates on earnings tax, VAT or National Insurance.

She blamed an "unpredictable world" with growing geopolitical and commercial concerns for the Budget revenue measures, likely to be focused on those "most able to pay."

International Trade Disputes

Addressing concerns about the UK's commercial links with China she said: "The UK's security interests invariably are paramount."

Recent announcement by Chinese authorities to tighten trade restrictions on rare earths and other materials that are crucial for high-technology manufacturing led US President Donald Trump to suggest an further 100% tariff on goods from the Asian country, increasing the possibility of an all-out trade war between the two largest economies.

The US Treasury Secretary labeled the Chinese action "commercial pressure" and "a global supply chain control attempt."

Questioned on accepting the American proposal to join its battle with China, the Chancellor said she was "very concerned" by China's measures and encouraged the Beijing authorities "not to put up barriers and limit trade."

She said the action was "harmful for the global economy and causes additional challenges."

"It is my opinion there are areas where we must address Chinese policies, but there are also important prospects to sell into China's economy, including banking sector and other sectors of the economy. We've got to achieve that equilibrium correct."

The chancellor also affirmed she was cooperating with international partners "regarding our own critical minerals approach, so that we are less reliant."

Health Service Medicine Pricing and Funding

The Chancellor also acknowledged that the cost the National Health Service spends on pharmaceuticals could increase as a consequence of ongoing discussions with the US government and its pharmaceutical firms, in return for reduced taxes and capital.

A number of the world's largest drug companies have said lately that they are either pausing or scrapping investments in the United Kingdom, with some attributing the modest returns they are receiving.

Last month, the Science Minister said the price the health service pays for medicines would must increase to halt companies and drug research funding leaving the United Kingdom.

Reeves told the BBC: "It has been observed because of the payment system, that clinical trials, new drugs have not been offered in the UK in the extent that they are in other EU nations."

"The objective is to make sure that patients getting treatment from the National Health Service are able to access the best life-saving treatments in the world. And so we are looking at this situation, and... aiming to attract more capital into the UK."